The Future of Health Technology Assessment in Healthcare Decision Making in Asia
- 299 Downloads
Most countries have healthcare resource constraints and it is easy to identify new health technologies as an area in need of resource management, particularly given that new health technologies usually increase rather than save costs. Resource constraints are even more noticeable in Asia than in other regions, with a comparatively greater speed of population aging and the development of health security systems. The healthcare industry and policy makers in Asia generally understand that rationing in healthcare delivery is inevitable and have come to accept health technology assessment (HTA) as a policy option.
The HTA policy framework is slowly penetrating Asia; South Korea was the first country to regulate the use of pharmacoeconomic evidence in drug reimbursement decision making. The South Korean HTA policy was initially a surprise in Asia in that the policy was suddenly introduced with a short period of preparation, but industry, researchers and policy makers both in- and outside of South Korea have come to accept it as necessary and logical.
Thailand and Taiwan have also taken steps towards using pharmacoeconomic evidence in HTA, while other Asian countries are planning to implement such policies. However, it could be some time before a legitimate pharmacoeconomic-based HTA policy is actually implemented in each country, and the course of action will vary depending on the policy culture, healthcare system and public trust in bureaucracy of each country.
KeywordsNational Health Insurance Health Technology Assessment Reimbursement Decision Health Technology Assessment Report Reimbursement List
No sources of funding were used to assist in the preparation of this article. The author has no conflicts of interest that are directly relevant to the content of this article.
- 1.Evidence-based decision making in Asia-Pacific health care systems of ten countries. 3rd Asia-Pacific ISPOR Conference; 2008 Sep 7-9; SeoulGoogle Scholar
- 3.ISPOR HTA Council Asia-Pacific, 3rd Asia-Pacific ISPOR Conference; 2008 Sep 7-9; SeoulGoogle Scholar
- 6.Health Insurance Review and Assessment Service. Guidelines for economic evaluation of pharmaceuticals in Korea. Seoul: HIRA, 2005Google Scholar
- 7.Health Insurance Review and Assessment Service. List of pharmaceuticals in national health insurance. Seoul: HIRA, 2006Google Scholar
- 8.Ministry of Health and Welfare. Implementation of positive list system policy. Seoul: Government of Korea, 2007Google Scholar
- 9.Kim S. Health Insurance Review and Assessment Service workshop. Seoul: HIRA, 2006 JanGoogle Scholar
- 10.Minutes from Health Insurance Reform Committee Meetings, Ministry of Health and Welfare, Government of Korea, 2004Google Scholar
- 11.HIRA report. Seoul: HIRA, 2007 (Data on file)Google Scholar
- 12.Special Panel Discussion Session on the Policy of Reevaluation of the Reimbursement Listed Drugs. Seoul: Daily-Pharm News, 2009 Jan 13Google Scholar
- 13.Yang BM, Kim CJ, Choi DH, et al. Cost-effectiveness of clopidogrel in acute coronary syndromes in South Korea. Seoul: Seoul National University, 2008Google Scholar
- 14.Department of Health. National health expenditure. Taipei: Government of Taiwan, 2006 [online]. Available from URL: (http://www.gio.gov.tw/taiwan-website/5-gp/yearbook/ch15.html) [Accessed 2008 Aug 1]Google Scholar
- 15.Huang N. Health technology assessment issues in Taiwan [presentation]. Pricing and Reimbursement Evidence Board Meetings; 2008 Jun 10; BangkokGoogle Scholar
- 16.Tarn YH. The experience of HTA agency in Taiwan [presentation]. 2008 International HTA Symposium; 2008 Aug 11; TaipeiGoogle Scholar
- 17.Yang M-C. Health policy and planning in Taiwan [presentation]. 1st Asia-Pacific Conference in Health Policy and Planning in an Era of Emerging Technology and Cancer; 2008 Nov 18; Kuala LumpurGoogle Scholar
- 18.Chaiyakunapruk N. Health technology assessment in Thailand [presentation]. Pricing and Reimbursement Evidence Board Meetings; 2008 Jun 10; BangkokGoogle Scholar
- 19.WHO Statistical Information System (WHOSIS), 2008 [online]. Available from URL: (http://www.who.int/whosis/data/search.jsp?countries=[Location].Members) [Accessed 2008 Aug 1]
- 20.Hanvoravongchai P. Health system and equity perspectives in health technology assessment. J Med Assoc 2008 Jun; 91 (2 Suppl.): 74S–87SGoogle Scholar
- 21.Wibulpolprasert S. The need for guidelines and the use of economic evidence in decision making in Thailand: lessons learnt from the development of the national list of essential drugs. J Med Assoc Thai 2008 June; 91 (2 Suppl.): 1S–3SGoogle Scholar
- 22.Teerawattananon Y. Health technology assessment in Thailand: turning a troubled teen into a successful adult. International Health Technology Assessment Symposium; 2008 Aug 1; TaipeiGoogle Scholar
- 23.English version of THTAG. J Med Assoc Thai 2008 Jun; 91 (2 Suppl.): S11–S65Google Scholar
- 24.Kapol N, Maitreemit P, Rapeepun C, et al. Making health technology assessment information available for decision making: the development of a Thai database. J Med Assoc Thai 2008 Jun; 91 (2 Suppl.): 8S–10SGoogle Scholar
- 25.Tangcharoensathien V, Kamolratanakul P. Making sensible rationing: the use of economic evidence and the need for methodological standards. J Med Assoc Thai 2008 Jun; 91 (2 Suppl.): 4S–7SGoogle Scholar
- 27.Retherford R, Westley S, Choe M, et al. The future of population in Asia. Honolulu: University of Hawaii, 2002.Google Scholar